Amit Munshi, ReNAgade Therapeutics CEO
May 23, 2023 06:00 AM EDTUpdated 12:37 PM
Financing
Bioregnum

Amit Mun­shi has more than $300M and a start­up CSO out to pi­o­neer next-gen RNA ther­a­peu­tics. Once again, he’s think­ing big

Amit Mun­shi had to beg off when he was first in­tro­duced to the idea of run­ning an MPM BioIm­pact stealth play­er named Re­NA­gade Ther­a­peu­tics. He …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

Boehringer’s up­dat­ed re­sults in HER2-mu­tat­ed lung can­cer im­press

No­vavax re­sponds to FDA’s tri­al ask, with Covid vac­cine strain up­dates un­der scruti­ny

GSK’s check­point block­er Jem­per­li cures bio­mark­er-dri­ven rec­tal can­cer

Mer­ck KGaA to buy rare can­cer biotech Spring­Works for $3.9B

Schol­ar Rock names new CEO, adds biotech vet­er­ans in C-suite re­build

sponsored

Rev­o­lu­tion­iz­ing obe­si­ty treat­ment: Could mi­to­chon­dria hold the key to un­lock­ing fat-spe­cif­ic weight loss?

A service from the Financial Times